Biogaia writes off allergy study

By Stephen Daniells

- Last updated on GMT

Related tags Lactobacillus

Disappointing results from a two-year investigation into the
effects of probiotics on allergies have forced Sweden's Biogaia to
end the research.

The firm said yesterday that it has decided to write-off capitalized development expenditures relating to the research.

Peter Rothschild, managing director of Biogaia, told that is was more prudent to write off the expenses than to continue with an unrewarding study.

The results will disappoint others in the industry who had believed in the ability of probiotic bacteria to help prevent allergies like eczema and asthma if taken from birth.

BioGaia's clinical study was launched in 2001, with 232 newborn infants being given Biogaia's patented Reuteri bacteria. The incidence of eczema, which is the main allergy for young infants, did not decrease with the probiotic supplement.

"It is of course a disappointment that the study did not show the results we expected,"​ said Rothschild.

However he drew some positives from the study, pointing out that there was reduced wheezing among two-year-old infants. Hay fever and asthma are uncommon in early life and this, says Rothschild, shows "clear tendencies that should be examined in future studies."

"We are optimistic that a possible follow-up of the study at a later stage will show reduced incidences of asthma and hay fever,"​ he added.

The results come just as the small firm approaches profitability. It has written off SEK 10.8 million (€1.15m) in development expenses, and SEK 4.9 million (€0.5m) to reverse provisions for future commitments to pay royalties on future sales of allergy products. Cash flow will not be affected however.

BioGaia said in a statement that it still had a "strong portfolio of innovative products, successful clinical trials and a growing distribution network covering a large share of the key markets"​.

Known as Reuteri, the lactic acid bacterium Lactobacillus reuteri​ has previously been shown to improve gastrointestinal, immune and oral health.

Related topics R&D Ingredients

Related news

Related products

show more

Unlock the business potential of the protein trend

Unlock the business potential of the protein trend

Content provided by Valio | 08-Feb-2024 | White Paper

Read our white paper to learn how to overcome taste and texture challenges in protein products — and how to commercialise the protein trend by making delicious...

Custom Microbiome Solutions for Dairy & Alt-Dairy Products

Custom Microbiome Solutions for Dairy & Alt-Dairy Products

Content provided by ADM: Innovation that Feeds the Future | 13-Oct-2023 | White Paper

Backed by clinical studies and perfect for use in dairy and alt-dairy applications alike, ADM’s Active Lifestyle probiotic blend, BPL1™ probiotic, and...

Consumers Want Dairy—and More!

Consumers Want Dairy—and More!

Content provided by ADM: Innovation that Feeds the Future | 06-Oct-2023 | White Paper

In the thriving dairy industry, you’re well aware of the surging demand for both dairy and non-dairy products.

Related suppliers

Follow us


View more